- Home
- PTGX vs AXSM Comparison
PTGX vs AXSM Comparison
Compare PTGX & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- AXSM
- Stock Information
- Founded
- PTGX 2006
- AXSM 2012
- Country
- PTGX United States
- AXSM United States
- Employees
- PTGX N/A
- AXSM N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- PTGX Health Care
- AXSM Health Care
- Exchange
- PTGX Nasdaq
- AXSM Nasdaq
- Market Cap
- PTGX 5.0B
- AXSM 5.9B
- IPO Year
- PTGX 2016
- AXSM 2015
- Fundamental
- Price
- PTGX $86.22
- AXSM $148.00
- Analyst Decision
- PTGX Strong Buy
- AXSM Strong Buy
- Analyst Count
- PTGX 9
- AXSM 20
- Target Price
- PTGX $86.44
- AXSM $176.00
- AVG Volume (30 Days)
- PTGX 914.5K
- AXSM 587.6K
- Earning Date
- PTGX 11-06-2025
- AXSM 11-03-2025
- Dividend Yield
- PTGX N/A
- AXSM N/A
- EPS Growth
- PTGX N/A
- AXSM N/A
- EPS
- PTGX 0.72
- AXSM N/A
- Revenue
- PTGX $209,217,000.00
- AXSM $561,263,000.00
- Revenue This Year
- PTGX N/A
- AXSM $63.66
- Revenue Next Year
- PTGX $140.23
- AXSM $54.46
- P/E Ratio
- PTGX $118.58
- AXSM N/A
- Revenue Growth
- PTGX N/A
- AXSM 65.83
- 52 Week Low
- PTGX $33.70
- AXSM $75.56
- 52 Week High
- PTGX $93.25
- AXSM $149.50
- Technical
- Relative Strength Index (RSI)
- PTGX 66.35
- AXSM 69.55
- Support Level
- PTGX $82.06
- AXSM $136.00
- Resistance Level
- PTGX $86.95
- AXSM $149.50
- Average True Range (ATR)
- PTGX 3.03
- AXSM 5.50
- MACD
- PTGX -0.04
- AXSM 0.45
- Stochastic Oscillator
- PTGX 92.09
- AXSM 96.05
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.